NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free ATXI Stock Alerts $4.78 +0.01 (+0.21%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$4.77▼$5.4550-Day Range$4.51▼$14.4052-Week Range$4.38▼$93.75Volume285,996 shsAverage Volume57,840 shsMarket Capitalization$2.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainability Get Avenue Therapeutics alerts: Email Address Avenue Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy32.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment-0.08Based on 38 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.50 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avenue Therapeutics. Previous Next 4.0 Short Interest Percentage of Shares Shorted32.81% of the outstanding shares of Avenue Therapeutics have been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently decreased by 31.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvenue Therapeutics has received a 73.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Avenue Therapeutics is -0.99. Previous Next 1.1 News and Social Media Coverage News SentimentAvenue Therapeutics has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Avenue Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 3 people have searched for ATXI on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesMay 3, 2024 | msn.comMultiple lane closures coming to Capitol Avenue in downtown IndyMay 3, 2024 | msn.comPickup truck hits girl, flees the scene on Lamar AvenueMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).May 2, 2024 | msn.com2 people in critical condition after shooting on Arlington Avenue in ChattanoogaMay 2, 2024 | msn.comCrash with injuries, entrapment reported on Hamilton Avenue in Springfield TownshipMay 2, 2024 | msn.comMelrose Avenue record shop celebrates vinyl albums, takes music collectors on a journey through timeMay 2, 2024 | msn.comBrickell Avenue is the priciest commercial street in MiamiMay 2, 2024 | msn.comMilwaukee's National Avenue will see its auto lanes cut. Other safety changes are comingMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).May 2, 2024 | msn.comCity Avenue in Lower Merion set to triple its apartment count, transforming the office and retail hubMay 2, 2024 | msn.comGirl critically injured in hit-and-run on Lamar AvenueMay 2, 2024 | msn.com'It's wholesome': Houston Avenue church to host gospel rap concert to spread love in communityMay 2, 2024 | msn.comMeeting held about 'rightsizing' Penn Avenue in the Strip DistrictMay 1, 2024 | msn.comPittsburgh International Jazz Festival brings free concerts to Liberty AvenueMay 1, 2024 | msn.comMan found shot multiple times along Cleveland AvenueApril 30, 2024 | msn.comSilver Diner Opening In The Avenue At White Marsh With Reimagined MenuApril 30, 2024 | yahoo.comCar crashes into Flying Burrito on College Avenue in FayettevilleApril 30, 2024 | msn.comWhy one block of Acero Avenue in Pueblo is being converted to a one-way streetApril 30, 2024 | startribune.comSt. Paul restores Rondo Avenue name to city streetApril 30, 2024 | msn.comIWC Schaffhausen Fetes New Boutique for Madison Avenue Watch WeekApril 30, 2024 | yahoo.comMadison Avenue Watch Week Returns With Breitling, Ralph Lauren, Apple and Others, After Pandemic HiatusApril 30, 2024 | msn.com2 Oak Lawn Men ID’d In Deadly Crash At 87th Street and Cicero AvenueApril 29, 2024 | msn.comReported crash with injuries in Reading on East Columbia AvenueApril 29, 2024 | msn.comPart of Starbuck Avenue to be closed on MondayApril 29, 2024 | msn.comDC Small Business Week kicks off with showcase along Rhode Island AvenueApril 29, 2024 | msn.comWhy Avenue Therapeutics (ATXI) Stock Is Falling SharplyApril 29, 2024 | msn.comEast Passyunk Flavors on the Avenue Breaks Attendance RecordsSee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/04/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($95.4887) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-335.11% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book2.49Miscellaneous Outstanding Shares590,000Free Float578,000Market Cap$2.82 million OptionableNot Optionable Beta-0.09 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 56)CEO & Director Comp: $413.2kMr. David Jin (Age 33)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Xiaoqin Lu M.D. (Age 49)Consultant Comp: $1.05MDr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kMr. Srinivas Subramanian (Age 53)Executive Vice President More ExecutivesKey CompetitorsAraviveNASDAQ:ARAVNovaBay PharmaceuticalsNYSE:NBYBiophytisNASDAQ:BPTSAridis PharmaceuticalsNASDAQ:ARDSAgile TherapeuticsNASDAQ:AGRXView All CompetitorsInsidersFortress Biotech, Inc.Bought 5,578 shares on 9/8/2023Total: $301,212.00 ($54.00/share)Lindsay A Md RosenwaldBought 4,649 shares on 9/8/2023Total: $251,046.00 ($54.00/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. How have ATXI shares performed in 2024? Avenue Therapeutics' stock was trading at $12.0750 at the start of the year. Since then, ATXI shares have decreased by 60.4% and is now trading at $4.78. View the best growth stocks for 2024 here. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 283,100 shares, a drop of 9.7% from the March 15th total of 313,400 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is currently 0.1 days. View Avenue Therapeutics' Short Interest. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its earnings results on Monday, March, 18th. The company reported $42.00 earnings per share for the quarter. When did Avenue Therapeutics' stock split? Shares of Avenue Therapeutics reverse split on the morning of Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXI) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.